卡格列净与利拉鲁肽改善β细胞葡萄糖敏感性在降低2型糖尿病HbA1c中起主要作用
该研究纳入45例血糖控制不佳的2型糖尿病患者,随机接受利拉鲁肽、卡格列净或两药联合治疗16周,治疗前后行口服葡萄糖耐量试验。三种方案均显著降低HbA1c并改善β细胞葡萄糖敏感性,联合治疗对HbA1c无显著额外效应,β细胞葡萄糖敏感性改善是HbA1c下降的最强预测因子。
要点
- 利拉鲁肽、卡格列净及联合治疗16周均显著降低HbA1c。
- 联合治疗对HbA1c的降低无显著叠加效应。
- β细胞葡萄糖敏感性改善是各治疗HbA1c下降的最强预测因子。
核心结论
- 卡格列净单药、利拉鲁肽单药或两药联合治疗所改善的β细胞葡萄糖敏感性是HbA1c下降的主要因素。
- 卡格列净未能产生优于利拉鲁肽的改善β细胞葡萄糖敏感性的叠加效应。
研究设计与样本
- 研究纳入45例血糖控制不佳(HbA1c=7%-11%)的2型糖尿病患者。
- 患者在16周治疗前后接受口服葡萄糖耐量试验,治疗分为利拉鲁肽组、卡格列净组和卡格列净联合利拉鲁肽组。
主要发现
- 利拉鲁肽、卡格列净及联合治疗分别降低HbA1c 0.89%、1.43%和1.67%,联合治疗对HbA1c无显著叠加效应。
- 口服葡萄糖耐量试验中∆C-Pep/∆G0-120在卡格列净组从0.30±0.06升至0.48±0.10,利拉鲁肽组从0.29±0.05升至0.98±0.23,联合组从0.24±0.06升至1.09±0.12;卡格列净组 vs 利拉鲁肽组 P=0.02,联合组 vs 卡格列净组 P<0.0001。
- β细胞葡萄糖敏感性在卡格列净组从29±5升至55±11,利拉鲁肽组从33±6升至101±16,联合组从28±6升至112±12;卡格列净组 vs 利拉鲁肽组 P=0.01,联合组 vs 卡格列净组 P<0.0001。
- 利拉鲁肽组与联合组在胰岛素分泌增加或β细胞葡萄糖敏感性增加方面无显著差异。
- HbA1c下降与β细胞葡萄糖敏感性增加呈强负相关(r=0.71,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To examine the effect of combination therapy with canagliflozin plus liraglutide versus each agent alone on beta cell function in type 2 diabetes mellitus (T2DM) patients. RESEARCH DESIGN AND METHODS: A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA). RESULTS: Both liraglutide and canagliflozin significantly lowered HbA1c with no significant additive effect of the combination on HbA1c (0.89%, 1.43%, and 1.67% respectively). Insulin secretion during the OGTT, measured with (∆C-Pep/∆G)0-120, increased in the 3 groups (from 0.30 ± 0.06 to 0.48 ± 0.10; 0.29 ± 0.05 to 0.98 ± 0.23; and 0.24 ± 0.06 to 1.09 ± 0.12 in subjects receiving CANA, LIRA and CANA/LIRA respectively; P = 0.02 for CANA vs LIRA, P < 0.0001, CANA/LIRA vs CANA), and the increase in insulin secretion was associated with an increase in beta cell glucose sensitivity (29 ± 5 to 55 ± 11; 33 ± 6 to 101 ± 16; and 28 ± 6 to 112 ± 12, respectively; P = 0.01 for CANA vs LIRA, P < 0.0001, CANA/LIRA vs CANA). No significant difference in the increase in insulin secretion or beta cell glucose sensitivity was observed between subjects in LIRA or CANA/LIRA groups. The decrease in HbA1c strongly and inversely correlated with the increase in beta cell glucose sensitivity (r = 0.71, P < 0.001). In multivariate regression model, improved beta cell glucose sensitivity was the strongest predictor of HbA1c decrease with each therapy. CONCLUSION: Improved beta cell glucose sensitivity with canagliflozin monotherapy and liraglutide monotherapy or in combination is major factor responsible for the HbA1c decrease. Canagliflozin failed to produce an additive effect to improve beta cell glucose sensitivity above that observed with liraglutide.
引用
- Ali AM, Mari A, Martinez R, et al. Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. J Clin Endocrinol Metab. 2020. PMID: 32745202. doi:10.1210/clinem/dgaa494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。